Gemcitabine: Current role and future options in the treatment of ovarian cancer

Erika Fruscella, Daniela Gallo, Gabriella Ferrandina, Giuseppe D'Agostino, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review


Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients.

Original languageEnglish
Pages (from-to)81-88
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Oct 2003


  • Chemotherapy
  • Gemcitabine
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Gemcitabine: Current role and future options in the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this